导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.91% | 1483/4773 |
| 近一周 | -2.04% | 1112/5462 |
| 近一月 | -3.52% | 1807/5421 |
| 近一季 | -5.94% | 1948/5209 |
| 近半年 | 0.58% | 1138/4920 |
| 近一年 | 5.07% | 1637/4366 |
| 近两年 | 48.99% | 1500/2954 |
| 近三年 | 31.61% | 986/2253 |
| 成立以来 | 51.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.45% 2793/4961 |
16.63% 1543/5312 |
- - |
- - |
| 2025 | 19.66% 2194/4813 |
-0.72% 2379/3635 |
2.76% 1379/4076 |
17.08% 2559/4524 |
0.18% 2150/4813 |
| 2024 | 14.79% 1004/3463 |
3.64% 529/2808 |
-0.98% 883/3014 |
15.17% 1796/3129 |
-2.87% 2196/3463 |
| 2023 | -7.66% 935/2656 |
4.33% 978/2280 |
-4.29% 1127/2385 |
-0.84% 455/2515 |
-6.74% 1900/2655 |
| 2022 | -21.14% 1012/2207 |
-14.54% 966/1919 |
7.05% 542/2016 |
-13.92% 995/2113 |
0.14% 1536/2208 |
| 2021 | 5.29% 550/1822 |
1.73% 245/1255 |
7.50% 682/1330 |
-3.29% 628/1466 |
-0.45% 1240/1822 |
| 2020 | 37.94% 370/1250 |
-8.90% 639/1028 |
15.01% 520/1067 |
14.50% 272/1164 |
14.99% 239/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘沪深300指数增强发起A VS. 长安沪深300非周期A(740101) |